When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?

This patient would not have qualified for the monarchE adjuvant abemaciclib protocol, which used pathologic staging for lymph node status (although baseline imaging was allowed for tumor size determination in patients who received adjuvant chemotherapy) (1). This is in contrast, for example, to the ...